Norway HIV Therapeutics Market Analysis Report [2022-30]

Norway HIV Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Norway HIV therapeutics market will reach a value of $xx Mn from $xx Mn in 2022, growing at a CAGR of xx% during 2022-2030. The market is primarily dominated by local players such as Mylan Healthcare Norge AS, Legebutikken, and AbbVie Norway. The market is driven by government policies and non-governmental organizations’ initiatives for the management of HIV infections in the country. The HIV therapeutics market in Norway is segmented by type, product, and geography, end user, and distribution channel.

ID: IN10NOPH037 CATEGORY: Pharmaceuticals GEOGRAPHY: Norway AUTHOR: Dr. Vishwa Modhia

Buy Now

Norway HIV Therapeutics Market Analysis Summary

By 2030, it is anticipated that the Norway HIV therapeutics market will reach a value of $xx Mn from $xx Mn in 2022, growing at a CAGR of xx% during 2022-2030.

Norway is a Northern European country that shares boundaries with the North Sea, the North Atlantic Ocean, Finland, Sweden, and Russia. According to the most recent WHO figures, the number of HIV/AIDS-related deaths in Norway will reach 100 by 2020. Norway ranks 151st in the world, with a death rate of 0.15 per 100,000 inhabitants. Adult HIV/AIDS prevalence in Norway was less than 0.1 percent in 2021, with 5800 HIV cases in 2020.

Norway has one of the highest shares among the approximately 20 countries judged to have met the targets. Norway is seeing an increase in the use of pre-exposure prophylaxis (PrEP) to prevent HIV transmission in high-risk populations. The increasing prevalence of drug-resistant HIV strains necessitates the development of new and creative treatments. The rising prevalence of drug-resistant strains of HIV leads to a greater need for new and innovative HIV drugs. Norway spent 11.4% of its GDP on healthcare in 2019.

Market Dynamics

Market Growth Drivers

With 93% of people living with HIV diagnosed, 98% receiving treatment, and 96% virally suppressed, around 87% of people living with HIV in Norway have achieved viral suppression. This is one of the highest shares among the about 20 countries regarded to have achieved the targets. Norway estimated at the end of 2018 that around 5 000 people in Norway are living with HIV and that 7-10% of them do not know their HIV status (355-520 undetected infections) based on data from the Norwegian Surveillance System for Communicable Diseases (MSIS). This opens the door for additional HIV therapeutics to be purchased.

Market Restraints

Due to Norway's low HIV prevalence in comparison to other nations, the patient population is limited. Individuals living with HIV may be discouraged from seeking testing and treatment due to stigma and discrimination. These considerations may discourage new businesses into the Norwegian HIV therapeutics market.

Competitive Landscape

Key Players

AbbVie Norway (NOR)
ViiV Healthcare Norway (NOR)
Legebutikken (NOR)
Mylan Healthcare Norge AS (NOR)
Merck & Co
Roche

Healthcare Regulations and Reimbursement Policies

The Norwegian Medicines Agency (NOMA) regulates HIV therapeutics in Norway in accordance with European Union (EU) regulations. NOMA is in charge of evaluating and authorizing the marketing of HIV medications, as well as monitoring their safety and ensuring that they meet quality standards. The agency collaborates with the European Medicines Agency (EMA) to ensure that HIV therapeutics are safe, effective, and of high quality in Norway.

In Norway, HIV therapeutics are reimbursed through the Norwegian Health Economics Administration's national public health insurance system (HELFO). HIV therapeutics are included in the "blue prescription scheme," a list of drugs and medical devices that are eligible for reimbursement. If a patient with HIV meets certain criteria, such as having a valid prescription from a licensed physician and being enrolled in the national health insurance program, they may be eligible for medication reimbursement. The positive results for the second and third 90 targets reflect the quality of HIV treatment in Norway. HIV treatment is free, and it includes close, specialized follow-ups as well as free check-ups for everyone in the country.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

HIV Therapeutics Segmentation

By Types (Revenue, USD Billion):

Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Coreceptor Antagonists
Entry and Fusion Inhibitors
Integrase Inhibitors
Protease Inhibitors (PIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.